Objective To study the clinical efficacy of combination of taxinol combined with anthracycline for advanced breast cancer preoperative chemotherapy. Methods 82 patients with unilateral primary breast cancer were selected and divided into two groups based on different chemotherapy regimens. 41 cases in control group received the cyclophosphamide and epirubicin ( EC ) chemotherapy regi-men, and 41 cases in combination group received taxinol and anthracycline regimen. 12 months after treatment, local evaluations of breasts, oxter and clavicle lymph nodes were carried out via Doppler ultrasonography, and systemic evaluations were realized by CT and bone scan. The pCR ( complete remission ) , CR+PR ( objective response rate ) and lymph node negative rate were compared in two groups. Results Follow-up visit and therapeutic effect evaluation were conducted during 12 months after treatment, the results showed that the CR+PR ( objective response rate ) in combination group was significantly higher than that of control group, with a statistically significant difference ( P 0. 05 );the pCR ( complete remission ) in combination group was significantly higher than that of control group, with a statistically significant difference ( P 0. 05 ) . No statistically significant differences were found in lymph node negative rate between combination and control group ( P > 0. 05 ) . Conclusion The clinical efficacy of taxinol combined with anthracycline regimen for breast cancer preoperative chemotherapy is more significant than the chemotherapy regimen of cyclophos-phamide and epirubicin ( EC ) .%目的：探讨紫杉类药物联合蒽环类药物对晚期乳腺癌术前化学治疗（简称化疗）的临床疗效。方法将收治的单侧原发乳腺癌患者82例按化疗方案不同分为两组，对照组41例行环磷酰胺、表阿霉素（EC）化疗方案，联合组41例行紫杉类联合蒽环方案。治疗后12个月两组均行双乳、腋下、锁骨上下淋巴结多普勒超声检查作局部评估，全身评估采用CT和骨扫描检查。比较两组完全缓解( CR )、客观有效率（CR+PR）、淋巴结阴性率。结果两组化疗后12个月随访并进行疗效评估，结果显示联合组的客观有效率（CR+PR）明显高于对照组，差异有统计学意义( P0．05)；联合组的病理CR率明显高于对照组，差异有统计学意义( P 0．05)。联合组、对照组治疗后淋巴结阴性率无显著性差异( P>0．05)。结论紫杉类药物联合蒽环方案对晚期乳腺癌术前化疗的临床效果较EC化疗方案更明显。
展开▼
